Catecholamines regulate tumor angiogenesis

Cancer Research

Volumn 69, Issue 9, 2009, Pages 3727-3730

  Chakroborty, Debanjan ^a   Sarkar, Chandrani ^a   Basu, Biswarup ^b   Dasgupta, Partha Sarathi ^b   Basu, Sujit ^a,b,c  

^a OHIO STATE UNIVERSITY   (United States)

^b CHITTARANJAN NATIONAL CANCER INSTITUTE   (India)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ADRENERGIC RECEPTOR; ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CATECHOLAMINE; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR STIMULATING AGENT; NORADRENALIN; VASCULOTROPIN; VASCULOTROPIN A;

ANGIOGENESIS; CANCER GROWTH; CANCER INHIBITION; DOWN REGULATION; HEMATOPOIETIC STEM CELL; HUMAN; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; OVARY HYPERSTIMULATION; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; UPREGULATION;

ANGIOGENESIS INHIBITORS; ANGIOGENIC PROTEINS; ANIMALS; CATECHOLAMINES; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 65949114869     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-4289     Document Type: Review

References (24)

1. Dvorak HF. Angiogenesis:update 2005. J Thromb Haemost 2005;3:1835-42. PubMed doi:10.1111/j.1538-7836.2005.01361.x.
2. Asahara T, Masuda H, Takahashi T, et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 1999;85:221-8. PubMed.
3. Heissig B, Hattori K, Dias S, et al. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell 2002;109:625-37. PubMed doi:10.1016/S0092-8674 (02) 00754-7.
4. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005;438:967-74. PubMed doi:10.1038/nature04483.
5. Ellis LM, Hicklin DJ. VEGF-targeted therapy:mechanisms of anti-tumour activity. Nat Rev Cancer 2008;8:579-91. PubMed doi:10.1038/nrc2403.
6. Basu S, Nagy JA, Pal S, et al. The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor. Nat Med 2001;7:569-74. PubMed doi:10.1038/87895.
7. Chakroborty D, Chowdhury UR, Sarkar C, Baral R, Dasgupta PS, Basu S. Dopamine regulates endothelial progenitor cell mobilization from mouse bone marrow in tumor vascularization. J Clin Invest 2008;118:1380-9. PubMed doi:10.1172/JCI33125.
8. Thaker PH, Han LY, Kamat AA, et al. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med 2006;12:939-44. PubMed doi:10.1038/nm1447.
9. Lutgendorf SK, Cole S, Costanzo E, et al. Stress-related mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines. Clin Cancer Res 2003;9:4514-21. PubMed.
10. Yang EV, Sood AK, Chen M, et al. Norepinephrine upregulates the expression of vascular endothelial growth factor, matrix met alloproteinase (MMP) -2, and MMP-9 in nasopharyngeal carcinoma tumor cells. Cancer Res 2006;66:10357-64. PubMed doi:10.1158/0008-5472. CAN- 06-2496.
11. Goldstein DS, Eisenhofer G, Kopin IJ. Sources and significance of plasma levels of catechols and their metabolites in humans. J Pharmacol Exp Ther 2003;305:800-11. PubMed doi:10.1124/jpet.103.049270.
12. Ganong WF. Synaptic and junctional transmission. Ganong WF, editor. Review of medical physiology. New York:McGraw-Hill;2005. p. 85-120.
13. Glaser R, Kiecolt-Glaser JK. Stress-induced immune dysfunction: implications for health. Nat Rev Immunol 2005;5:243-51. PubMed doi:10.1038/nri1571.
14. Yang EV, Donovan EL, Benson DM, Glaser R. VEGF is differentially regulated in multiple myeloma-derived cell lines by norepinephrine. Brain Behav Immun 2008;22:318-23. PubMed doi:10.1016/j.bbi.2007.09.010.
15. Nilsson MB, Armaiz-Pena G, Takahashi R, et al. Stress hormones regulate interleukin- 6 expression by human ovarian carcinoma cells through a Src-dependent mechanism. J Biol Chem 2007;282:29919-26. PubMed doi:10.1074/jbc. M611539200.
16. Landen CN Jr, Lin YG, Armaiz Pena GN, et al. Neuroendocrine modulation of signal transducer and activator of transcription-3 in ovarian cancer. Cancer Res 2007;67:10389-96. PubMed doi:10.1158/0008-5472. CAN-07-0858.
17. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004;4:71-8. PubMed doi:10.1038/nrc1256.
18. Lutgendorf SK, Lamkin DM, Jennings NB, et al. Biobehavioral influences on matrix met alloproteinase expression in ovarian carcinoma. Clin Cancer Res 2008;14:6839-46. PubMed doi:10.1158/1078-0432. CCR- 08-0230.
19. Basu S, Sarkar C, Chakroborty D, et al. Ablation of peripheral dopaminergic nerves stimulates malignant tumor growth by inducing vascular permeability factor/vascular endothelial growth factor-mediated angiogenesis. Cancer Res 2004;64:5551-5. PubMed doi:10.1158/0008-5472. CAN-04-1600.
20. Chakroborty D, Sarkar C, Mitra Basu R, Banerjee S, Dasgupta PS, Basu S. Depleted dopamine in gastric cancer tissues:dopamine treatment retards growth of gastric cancer by inhibiting angiogenesis. Clin Cancer Res 2004;10:4349-56. PubMed doi:10.1158/1078-0432. CCR-04-0059.
21. Sarkar C, Chakroborty D, Chowdhury UR, Dasgupta PS, Basu S. Dopamine increases the efficacy of anticancer drugs in breast and colon cancer preclinical models. Clin Cancer Res 2008;14:2502-10. PubMed doi:10.1158/1078- 0432. CCR-07-1778.
22. Teunis MA, Kavelaars A, Voest E, et al. Reduced tumor growth, experimental metastasis formation, and angiogenesis in rats with a hyperreactive dopaminergic system. FASEBJ 2002;16:1465-7. PubMed.
23. Perron L, Bairati I, Harel F, Meyer F. Antihypertensive drug use and the risk of prostate cancer (Canada). Cancer Causes Control 2004;15:535-41. PubMed doi:10.1023/B:CACO.0000036152.58271.5e.
24. Alvarez C, Martí-Bonmatí L, Novella-Maestre E, et al. Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. J Clin Endocrinol Metab 2007;92:2931-7. PubMed doi:10.1210/jc.2007-0409.